o_19nh7smpi1u37npm1scb1pfbjrda.pdf

The uptake of lower-priced biosimilar versions of cetuximab and bevacizumab is expected to
rise, limiting the already-moderate growth of the market.
The roll-out of generic versions of capecitabine is also announced and is expected to hamper
the market growth to a great extent.
However, the launches of premium-priced developing therapies for the treatment of
colorectal cancer are expected to balance the market.
Stivarga (regorafenib tab) is expected to drive the colorectal cancer therapeutics market
significantly as its expected line extension is in the first-line metastatic setting, which will be
used as the maintenance treatment for patients, who have resected liver metastases.
Another drug, Lonsurf (TAS-102), approved in Japan for the treatment of advanced metastatic
colorectal cancer is gaining immense popularity among patients as it is more tolerable
compared to Stivarga.
Xilonix and Panitumumab are expecting their approval, after which they are projected to
trigger additional market growth.
Browse the full Press Release of Colorectal Cancer Therapeutics Market :
http://www.mrrse.com/colorectal-cancer-therapeutics-market-report
The future of colorectal cancer therapeutics market is showing signs of healthy growth
facilitated by potential drugs under various phases of clinical development and around 400
active pipeline molecules.
Pfizer Inc., Ingelheim, Bayer Healthcare Pharmaceuticals, Eli Lilly and Co., and Taiho
Pharmaceutical are the major participants operating in the colorectal cancer therapeutics
market.
Send An Enquiry: http://www.mrrse.com/enquiry/114
1 Table of Contents
1.1 List of Tables
1.2 List of Figures